Placebo for Mepolizumab Injection, MEPOLIZUMAB, Placebo for Depemokimab Injection
217102
Phase 3 small_molecule active
Quick answer
Placebo for Mepolizumab Injection, MEPOLIZUMAB, Placebo for Depemokimab Injection for Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy is a Phase 3 program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active